This site is intended for healthcare professionals residing in Canada.

Visit Pfizer AcademySearch

Menu

Close

Sign InLog Out
  • EN
ProductsTherapy AreasExplore ContentExplore
​​​​​​​Content
Go to Explore ContentEventsMaterialsVideosPatient SupportContactEN - EnglishSelect a languageLanguagesEN - EnglishFR - Français

Menu

Close

Home

Recommendations

SOGC Recommendations

NACI Recommendations

CIQ Recommendations

About RSV

About RSV

Infants at Risk

Individuals ≥ 60 Years of Age

About ABRYSVO

Reconstitution and Storage

Dosing and Administration

Mechanism of Action

Efficacy and Safety Profiles

Clinical Trials

MATISSE Study Design

MATISSE Data

MATISSE Safety Profile

RENOIR Study Design

RENOIR Data

RENOIR Safety Profile

More

Coverage Information

Patient Profiles

FAQ

Resources

Product MonographSafety Information
Pfizer Respiratory Vaccine Portfolio
Individuals ≥ 60 years of age are at high risk for severe infection Individuals ≥ 60 years of age are at high risk for severe infectionPooled RSV hospitalization rates across age groups (per 100,000)1* Certain chronic conditions increase the risk for severe RSV disease2
  • Cardiac or pulmonary disorders (COPD, asthma, etc.)
     
  • Diabetes and other metabolic diseases
     
  • Moderate and severe immunodeficiency
     
  • Chronic renal disease
     
  • Chronic liver disease
     
  • Neurologic or neurodevelopmental conditions
     
  • Obesity (BMI ≥ 40 kg/m2)
RSV: respiratory syncytial virus; COPD: chronic obstructive pulmonary disease; BMI: body mass index; SOGC: Society of Obstetricians and Gynaecologists of Canada; NACI: National Advisory Committee on Immunization; CIQ: Comité sur l’immunisation du Québec
*Based on a prospective Canadian surveillance study of adults 50 years and older hospitalized with respiratory illness.References:Statement on the prevention of respiratory syncytial virus (RSV) disease in older adults. National Advisory Committee on Immunization (NACI). July 2024. Government of Canada. Respiratory syncytial virus (RSV) vaccines: Canadian immunization guide. Accessed September 13, 2024. Available from: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/respiratory-syncytial-virus.html#a2.2.
About RSV
Recommendations

Learn more about SOGC, NACI, and CIQ recommendations.

About ABRYSVO

Find information about ABRYSVO.

PP-A1G-CAN-0117-EN

To report an adverse event, please call 1-866-723-7111

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out

© Pfizer Canada ULC 2024. All rights reserved. The information is intended only for healthcare professionals resident in Canada. ®Pfizer Inc., used under license.

PP-UNP-CAN-0145-EN
You are now leaving Pfizerpro.ca website
Links to other sites are provided as a convenience to the viewer, and should not be taken as an endorsement of the sites or an association with their owners. Pfizer Canada accepts no responsibility for the content of linked sites.
You are now leaving the PfizerPro Portal.
You are about to view resources made available by Pfizer Academy. 
These resources include learning programs and upcoming events. By selecting Go to link below, you acknowledge and certify that you are a Canadian Healthcare Professional.
PP-UNP-CAN-0013 EN
Are you a resident of Quebec?